
The board of Allergan (NYSE:AGN) named Douglas Ingram president following 17 years in other upper management roles at the Irvine, Calif., drug and device maker. Ingram was most recently president and executive VP of the company’s European, African and Middle East regions.
Ingram has worked a wide range of jobs at Allergan, including leading roles in compliance, internal audit controls, human resources, regulator affairs and public relations.
Ingram was a lawyer before joining Allergan in 1996, according to a company statement.
New VP of R&D will join AtriCure from Medtronic
Medtronic’s (NYSE:MDT) director of R&D for the structural heart business is slated to join AtriCure (NSDQ:ATRC) later this summer as VP of R&D. At Medtronic, he worked on radiofrequency and cryogenic surgical ablation technologies and designed the medtech giant’s Cardioblate irrigated ablation system. He holds 50 patents, and Twin Cities Business named him a top inventor in 2013.
Read more
As Exalenz Bioscience ramps up for market launch of its BreathID device, the company appointed Ted Foltyn as its new VP of worldwide marketing and business development. CEO Lawrence Cohen, who only stepped into the corner office this March, said Foltyn’s appointment is part an expanding marketing and BD team. Foltyn is a former senior director of sales and marketing at Johnson & Johnson (NYSE:JNJ).
Read more
PHT Corp., which develops systems to collect patient-driven electronic data, brought on a new operations chief. Steven Rosenberg previously worked as VP of software at Oracle Corp.’s health science and global business unit. He has more than 30 years of experience in Boston-area high-tech companies, according to PHT.
Read more
Mark Berg, who joined Titan Spine in 2010, was named the company’s new senior VP of global operations. He has worked for a number of medical device heavyweights, including DePuy, Medtronic Sofamor Danek and Biomet 3i.
Read more